TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to “Sell”

TuHURA Biosciences (NASDAQ:HURA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Several other analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Hold” and a consensus price target of $9.00.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $1.94 on Friday. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $4.44. The stock has a fifty day moving average of $1.18 and a 200 day moving average of $1.68. The firm has a market capitalization of $117.80 million, a price-to-earnings ratio of -3.88 and a beta of -0.30.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in TuHURA Biosciences by 42.6% during the fourth quarter. Barclays PLC now owns 52,615 shares of the company’s stock worth $40,000 after purchasing an additional 15,725 shares during the last quarter. State Street Corp increased its position in shares of TuHURA Biosciences by 4.9% during the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after purchasing an additional 13,594 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of TuHURA Biosciences by 109.0% during the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after purchasing an additional 19,931 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares in the last quarter. Finally, Invst LLC raised its holdings in shares of TuHURA Biosciences by 88.9% during the 4th quarter. Invst LLC now owns 42,506 shares of the company’s stock valued at $32,000 after buying an additional 20,006 shares in the last quarter. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.